Detailed Narrative
Medicare LCD Status
Lucid Diagnostics continues to await the publication of its draft Local Coverage Determination (LCD) from Medicare. Management acknowledges a broad backlog at CMS for LCD output but notes recent signs of this backlog loosening, with several long-awaited LCDs having been published. The company remains confident in securing a positive draft policy, which is considered the most important near-term milestone for broader reimbursement.
Commercial Coverage Breakthrough
The company secured its first laboratory benefit manager (LBM) commercial coverage policy from Concert. This policy deems EsoGuard medically necessary for patients meeting established screening criteria, validating its clinical evidence. Three of Concert's client health plans have already adopted this policy, with more expected in the coming months⏳. These plans cover nearly 10 million lives and are concentrated in specific geographic areas, which will help in resource allocation.
VA Market Progress
Engagement with the Department of Veterans Affairs (VA) is progressing well, with a robust pipeline of VA centers across the U.S. Clinical engagement has been extremely positive, with no pushback from clinicians. The primary focus is on securing contracts for the new federal fiscal year, which begins on October 1, and these contracts are expected to contribute to future test volume and revenue growth.
Health Economic Evidence
Lucid partnered with a lead author of the American College of Gastroenterology guidelines to develop a sophisticated cost-effectiveness model for EsoGuard screening. This model compares EsoGuard to current care across the at-risk population, assessing its impact on BE detection, esophageal cancer state shifting, avoidance, and mortality. Preliminary results are very encouraging, showing positive clinical impact and EsoGuard appearing cost-effective, with the full model expected to be completed and published this summer.
Health System Integration
Extensive work is underway with health systems as a major part of Lucid's commercialization strategy. This involves tailoring clinical workflows, supporting patient identification, ordering, and results, with EHR integration playing a crucial role in automating patient identification. This process, while taking time, is starting to yield results, with initial conversations translating into active implementation work and programs within multiple health systems.
Commercial Strategy Shift
Lucid is actively shifting its commercial strategy and incentive plans to focus more heavily on 'MVAC' (Medicare, VA, and contracted revenue), which includes self-insured employers and fire departments. This strategic pivot emphasizes getting paid for tests, moving away from less efficient channels like concierge medicine. This shift has already resulted in a substantial increase in the proportion of tests fitting the MVAC category in Q2 FY26.